J&J sales grow, but strong dollar tugs at expectations
2 years, 2 months ago

J&J sales grow, but strong dollar tugs at expectations

Associated Press  

Johnson & Johnson topped third-quarter expectations thanks to pharmaceutical sales growth, but a strong dollar made the health care giant tread cautiously again with its outlook. J&J on Tuesday narrowed its 2022 forecast and stuck to the midpoint of its previous range after lowering expectations earlier this year due to the impact of currency exchanges. Revenue from the company’s biggest segment, pharmaceutical, climbed 2.6% — or 9% without the impact of foreign exchange — to $13.2 billion. Sales climbed 2% in the company’s medical device segment, to $6.78 billion, while revenue slipped in consumer health.

Sales Company Billion Strong Dollar  earnings  grow  strong  dollar  billion  tugs  climbed  revenue  range  vaccine  company  segment  jj  sales  expectations

History of this topic

J&J to pump another $13B into its MedTech business with Shockwave deal
8 months, 2 weeks ago

J&J to pump another $13B into its MedTech business with Shockwave deal

Associated Press  

Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. J&J Chief Financial Officer Joseph Wolk told analysts on Friday that the market for this technology is still “in the early days of scaling up.” He said he sees room for more …

J&J sales in US rise 10%, health care giant raises dividend
1 year, 8 months ago

J&J sales in US rise 10%, health care giant raises dividend

Associated Press  

Johnson & Johnson beat first-quarter expectations, as growth in cancer treatments and the health care giant’s home market helped counter another revenue hit from the strong dollar. The health care giant booked a $68 million loss on a one-time charge in the quarter related to its baby powder, and revenue grew more than 5% to $24.75 billion, which was better …

J&J to buy cardio technology company Abiomed for $16.6B
2 years, 1 month ago

J&J to buy cardio technology company Abiomed for $16.6B

Associated Press  

Johnson & Johnson is spending more than $16 billion to move deeper into treating heart disease and continue a shift started last year away from its consumer health roots. The health care giant said Tuesday that it will buy the cardiovascular technology company Abiomed, which makes a heart pump used on patients with severe coronary artery disease. The deal is …

Strong Q2 at J&J, but outlook cut again due to dollar’s rise
2 years, 5 months ago

Strong Q2 at J&J, but outlook cut again due to dollar’s rise

Associated Press  

Johnson & Johnson rode sales of the cancer treatment Darzalex and other key drugs to a better-than-expected second quarter, but exchange rates again pinched the health care giant’s 2022 forecast. Sales of J&J’s one-shot COVID-19 vaccine, which debuted last year, totaled $544 million, with only $45 million coming from the United States. Outside pharmaceuticals, which make up J&J’s biggest business, …

Johnson & Johnson to split into 2, aim for faster growth
3 years, 1 month ago

Johnson & Johnson to split into 2, aim for faster growth

Associated Press  

Johnson & Johnson is peeling off a consumer health business that helped it become the world’s biggest health care products maker. CEO Alex Gorsky said that while the company’s broad focus has worked in the past, the split addresses segments that “have evolved as fundamentally different businesses.” “We’ve seen a significant evolution in these markets, particularly on the consumer side,” …

Discover Related